RANCHO CORDOVA, Calif., Oct. 21 /PRNewswire-FirstCall/ -- ThermoGenesis Corp. announced today that it will be a presenting company at the C.E. Unterberg, Towbin Emerging Growth Life Sciences Conference at The Palace Hotel in New York to be held on October 25 and 26, 2005.
Philip Coelho, Chief Executive Officer, will be attending the conference where he will deliver a presentation on Tuesday, October 25, 2005 at 8:20 a.m. EDT in the Holms room. In his presentation, Mr. Coelho will present an overview of the Company’s business activities and product pipeline.
For those who can not attend the conference, the presentation will be accessible through a live webcast. To listen to the presentation, connect to the following link up to 15 minutes prior to the 8:20 a.m., commencement of the presentation: http://www.wsw.com/webcast/ceut3/kool/ . The presentation will also be accessible for 90 days after the conference.
About ThermoGenesis Corp.
ThermoGenesis Corp. is a leader in enabling technologies for cell therapeutics. The Company’s technology platforms lead the world in their ability to produce biological products from single units of blood.
-- The BioArchive(R) System, an automated robotic cryogenic device, is used by major cord blood stem cell banks in 26 countries as a key enabling technology for cryopreserving and archiving stem cell units for transplant. -- The AutoXpress(TM) System, currently undergoing Alpha testing, is a semi-automated robotic device and companion sterile closed blood processing disposable, to harvest stem cells from cord blood. -- The CryoSeal(R) FS System, a semi-automated device and companion sterile blood processing disposable, is used to prepare hemostatic and adhesive surgical sealants from the patient’s blood in about an hour. Enrollment in a 150 patient U.S. pivotal clinical trial has been completed and a PMA is being prepared. -- The Thrombin Processing Device (TPD(TM)) is a sterile blood processing disposable that prepares activated thrombin from a small aliquot of patient blood, or blood plasma in 25 minutes. The TPD market launch is underway in Europe.
The statements contained in this release which are not historical facts are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements, including, but not limited to, certain delays beyond the company’s control with respect to market acceptance of new technologies and products, delays in testing and evaluation of products, and other risks detailed from time to time in the Company’s filings with the Securities and Exchange Commission.
ThermoGenesis Corp.
CONTACT: Philip Coelho of ThermoGenesis Corp., +1-916-858-5100
Web site: http://www.thermogenesis.com/
